If, after several weeks treatment you do not feel any improvement
March 8: As if it was possible for Novo Nordisks Wegovy to get any hotter, the FDA approved the GLP-1 weight loss drug to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease who are obese or overweight
One systematic review and meta-analysis found that, when used alongside standard treatments, these medications can significantly reduce body weight, BMI, and waist circumference
GLP-1 receptor agonists have been studied in clinical trials and have shown significant weight loss benefits for certain patients when combined with diet and exercise
One of the key stumbling blocks at this point was that most of the immunoassays then available relied on antibodies sourced from serum collected from immunised animals or humans, called polyclonal antiserum
The longevity-focused side of the internet has converged on two specific stacks: GLOW and KLOW
